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Introduction
During  skeletal  muscle  development,  cells  from  the  somites 
commit to myogenic lineage and progress along the myogenic 
pathway by proliferation, terminal differentiation, and formation 
of multinucleated myofibers (Buckingham, 2001). The entire 
process is guided by various environmental cues and regulated 
by distinct signaling pathways, resulting in the activation of 
specific transcription factors and subsequent reprogramming 
of gene expression (Weintraub, 1993; Lassar and Münsterberg, 
1994; Naya and Olson, 1999; Perry and Rudnick, 2000). Skeletal 
muscle regeneration is one of the adult muscle remodeling pro-
cesses, which involves satellite cell (or other types of muscle 
stem cell) activation, proliferation, and differentiation to form 
new myofibers (Wagers and Conboy, 2005). Muscle regeneration 
shares a high extent of regulatory mechanisms with embryonic 
myogenesis (Parker et al., 2003) and serves as an experimental 
model to study the regulation of skeletal myogenesis in vivo. 
Myogenesis is also largely recapitulated by in vitro culture of 
myoblasts, which, in response to serum withdrawal, exit the cell 
cycle, differentiate, and fuse to form myotubes.
The insulin-like growth factors (IGFs) have long been 
established to play critical roles in skeletal myogenesis both 
during development and in adult muscle remodeling (Florini 
et al., 1991a, 1996). IGF-II, an embryonic regulator of myogen-
esis and an autocrine factor that initiates myoblast differentiation   
in vitro (Florini et al., 1991b), is regulated at the transcriptional 
level through a muscle-specific enhancer by mammalian target 
of rapamycin (mTOR) signaling (Erbay et al., 2003). IGF-II 
translation has also been shown to be regulated by an RNA-
binding protein, LIN-28, during skeletal myogenesis (Polesskaya 
et al., 2007). Given its critical role in the initiation of myogene-
sis, it would not be surprising if the production of IGF-II dur-
ing myogenesis were under additional modes of regulation yet 
to be discovered.
MicroRNAs (miRNAs), 22-nt noncoding RNAs regulat-
ing gene expression at posttranscriptional levels, have emerged 
as key regulators for many developmental processes (Bushati 
and Cohen, 2007; Bartel, 2009), including skeletal myogenesis. 
The central role of miRNAs in skeletal muscle development has 
been demonstrated by the detrimental consequence of Dicer 
deletion in embryonic skeletal muscle (O’Rourke et al., 2007). 
Several muscle-specific miRNAs that control various aspects of 
myogenesis have been identified and characterized (Callis et al., 
2008; Williams et al., 2009). The best studied are the miR-1/206 
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(Hwang et al., 2009). Unlike primary myoblasts, which were 
differentiated at subconfluence, C2C12 cell differentiation was 
typically initiated at 100% confluence in our experiments. To   
assess any potential change in miR-125b levels caused by cell–cell 
contact, we compared confluent culture (differentiation day 0) and 
proliferating myoblasts at 60% confluence and found no differ-
ence in miR-125b levels (Fig. 1 A). Thus, miR-125b biogenesis 
did not seem to be influenced by cell density under our experi-
mental conditions.
Next, we assessed miR-125b expression during skeletal 
muscle regeneration in vivo in a mouse muscle injury model. 
We have recently shown that barium chloride (BaCl2) injection 
into the tibialis anterior (TA) muscle induces acute and severe 
myofiber degeneration on day 1 after injury (AI), followed by 
myofiber regeneration that reaches completion by days 21–28 
AI (Ge et al., 2009), which is consistent with previous studies 
by others (Caldwell et al., 1990; McArdle et al., 1994). The lev-
els of miR-1 and miR-206, two of the best-studied myogenic 
miRNAs, decreased on day 3 AI and then increased during the 
regeneration time course (Fig. S1), in full agreement with re-
ported observations (Greco et al., 2009; Chen et al., 2010). 
As shown in Fig. 1 C, miR-125b levels declined on days 5–7 AI, 
which is a period of active new myofiber formation (Ge et al., 
2009), and returned to the basal level after that. This temporary 
and miR-133 families, which regulate fundamental processes 
of  myogenesis  including  myoblast/satellite  cell  proliferation 
and differentiation under the control of myogenic transcription 
factors (Williams et al., 2009 and references therein). Addi-
tional miRNAs reported to function in skeletal myogenesis 
include miR-24 (Sun et al., 2008), miR-26a (Wong and Tellam, 
2008), miR-27b (Crist et al., 2009), miR-29 (Wang et al., 2008), 
miR-181  (Naguibneva  et  al.,  2006b),  miR-214  (Juan  et  al., 
2009), miR-221/222 (Cardinali et al., 2009), miR-486 (Small 
et al., 2010), and miR-208b/miR-499 (van Rooij et al., 2009). 
Direct targets in muscles have been identified for some of these 
miRNAs but not others. It would be reasonable to speculate 
that more myogenic miRNAs are yet to be discovered.
miR-125b, as well as its paralogue miR-125a, is the   
homologue of Caenorhabditis elegans lin-4, the first miRNA 
reported (Lee et al., 1993). Both miR-125a and miR-125b are 
highly expressed in mouse brains, but only miR-125b is easily 
detectable in several other tissues, including heart, lung, spleen, 
and skeletal muscle (Lagos-Quintana et al., 2002). miR-125 has 
been implicated in neuronal differentiation of mouse P19 cells 
by targeting the RNA-binding protein LIN-28 (Wu and Belasco, 
2005), and it also promotes neuronal differentiation in human 
cells by suppressing multiple targets (Le et al., 2009b). More-
over, it has been demonstrated that miR-125b targets p53 in 
stress-induced apoptosis (Le et al., 2009a). However, a function 
for miR-125b in skeletal muscle has never been reported despite 
its notable expression in the muscle. In this study, we report that 
miR-125b negatively modulates myoblast differentiation in vitro 
and muscle regeneration in vivo. We identify IGF-II as the molecu-
lar target of miR-125b in skeletal myogenesis. Furthermore, 
our results suggest that mTOR signaling controls the levels of 
miR-125b during myogenesis both in vitro and in vivo.
Results
miR-125b is down-regulated during 
myoblast differentiation in vitro and muscle 
regeneration in vivo
In an miRNA profiling that we had previously performed (Sun 
et al., 2010), miR-125b was found to be down-regulated during 
C2C12 myoblast differentiation. The closely related miR-125a 
was detected at a much lower level, which is consistent with 
the findings from other studies (Chen et al., 2006; Inose et al., 
2009), and unchanged upon differentiation (Sun et al., 2010). 
To confirm the down-regulation of miR-125b observed in our 
microarray experiments, we examined miR-125b levels by 
quantitative RT-PCR (qRT-PCR) in C2C12 cells induced to dif-
ferentiate by serum withdrawal, which formed mature myotubes 
by day 3 as we had previously reported (Erbay et al., 2003). 
Indeed, miR-125b levels decreased by 30% and 50% by days 
2 and 3 of differentiation, respectively (Fig. 1 A). A similar de-
crease of miR-125b levels was observed during differentia-
tion of mouse primary myoblasts (Fig. 1 B). This decrease of 
miR-125b during myoblast differentiation was observed by   
others as well (Polesskaya et al., 2007), although its functional 
significance remained unknown. A recent study suggested that 
cell–cell contact could activate miRNA biogenesis globally 
Figure 1.  miR-125b is down-regulated during myoblast differentiation 
and muscle regeneration. (A and B) C2C12 cells (A) and mouse primary 
myoblasts (B) were induced to differentiate at 100% and 60–70% conflu-
ence, respectively. Total RNA was isolated from the differentiating cells on 
various days as indicated (diff. day) and subjected to analysis by qRT-PCR 
to determine the relative levels of mature miR-125b. Proliferating C2C12 
myoblasts (MB) at 60% confluence were also examined in A. (C) Regen-
eration of TA muscles in mouse was induced by BaCl2 injury. On various 
days AI, total RNA was isolated from the TA muscles and subjected to 
analysis by qRT-PCR to determine the relative levels of mature miR-125b. 
Saline injection into contralateral TA muscles served as “no injury” control. 
The data in A and B are mean ± SD from three to four independent experi-
ments. The data in C are mean ± SD with four mice per time point. One-
sample t test was performed to compare each data point with the control 
(0 h or no injury). *, P < 0.05; **, P < 0.01.71 miR-125b targeting IGF-II in myogenesis • Ge et al.
differentiation index (percentage of nuclei in myosin heavy chain 
[MHC]–positive cells) and fusion index (percentage of nuclei in 
myocytes with at least two nuclei) as shown in Fig. 2 C. We also 
introduced a locked nucleic acid (LNA)–containing antisense 
miR-125b oligonucleotide, anti–miR-125b (Naguibneva et al., 
2006a), into C2C12 cells to antagonize endogenous miR-125b. 
An LNA-containing oligonucleotide of a scrambled sequence 
with no complementarity to any known miRNAs served as a 
negative control. Anti–miR-125b reduced the cellular level of 
miR-125b by 50% before the natural decline of miR-125b to 
a similar extent (Fig. 2 D), and this was accompanied by en-
hanced myotube formation (Fig. 2 B), as confirmed by increased 
differentiation and fusion indexes (Fig. 2 E). Anti–miR-125b 
did not change the cellular level of miR-125a (Fig. 2 F), validat-
ing the specificity of the antisense oligonucleotide. Two myogenic 
decrease of miR-125b expression during regeneration in vivo 
is in line with the pattern of miR-125b expression during myo-
blast differentiation, which suggests a potentially negative role 
of miR-125b in myogenesis.
miR-125b negatively regulates myoblast 
differentiation and muscle regeneration
To investigate a potential role of miR-125b in myoblast differ-
entiation, we introduced a synthetic RNA duplex of miR-125b 
into C2C12 myoblasts, which were then induced to differenti-
ate. As shown in Fig. 2 A, delivery of this duplex was highly ef-
fective, increasing cellular miR-125b levels by >10-fold. This 
exogenous miR-125b dampened C2C12 differentiation, as indi-
cated by decreased myotube formation (Fig. 2 B). Quantifi-
cation of the myotubes revealed significant decreases in both 
Figure 2.  miR-125b negatively regulates myoblast differentiation. C2C12 myoblasts were transfected with 50 nM RNA duplexes or LNA-containing 
oligonucleotides and then were induced to differentiate 1 d later for 3 d. An siRNA against EGFP (siEGFP) and an LNA oligonucleotide with scrambled 
sequence (LNA-Scr) served as negative controls for miR-125b duplex and anti–miR-125b, respectively. (A and D) Relative miR-125b levels were measured 
by qPCR in nontransfected cells (control) and cells transfected with various oligonucleotides, as indicated, during the course of differentiation (diff.). (B) The 
differentiated cells were fixed, and immunostained for MHC (green) and DAPI (red). Bar, 100 µm. (C and E) Differentiation and fusion indexes were quanti-
fied. (F) Relative miR-125a levels were measured by qPCR 1 d after transfection of LNA oligonucleotides (same as diff. day 0). (G) Western blot analysis of 
cells treated as described in A. In B and G, representative results of at least three independent experiments are shown. All quantitative data are shown as 
mean ± SD from three to four independent experiments. For the qPCR data (A, D, and F), one-sample t tests were performed to compare each data point 
against control on day 0 (A and D) or between LNA-Scr and anti–miR-125b (F). For the differentiation and fusion index data (C and E), paired t tests were 
performed to compare data within each time point. *, P < 0.05; **, P < 0.01.JCB • VOLUME 192 • NUMBER 1 • 2011   72
miR-125b or anti–miR-125b did not change the cell number by 
the end of differentiation (Fig. S2 C). Thus, miR-125b does not 
appear to regulate myoblast proliferation or survival but rather 
has a specific role in myoblast differentiation.
To probe the function of miR-125b in muscle regenera-
tion in vivo, we introduced miR-125b duplex and, separately, 
LNA-containing anti–miR-125b into the muscle injury site by 
coinjecting the oligonucleotides with BaCl2. Muscle regeneration 
was then examined on days 5, 7, and 14 AI. Representative cross 
sections of regenerating muscle on day 7 AI are shown in Fig. 3 A; 
exogenous miR-125b impaired regeneration, as indicated by the 
incomplete restoration of muscular structure at the injury site. 
Injection of any of the oligonucleotides in the absence of BaCl2 
had no detectable effect on the muscles (Fig. 3 A, saline panels). 
Regenerating myofibers, characterized by their centrally local-
ized nuclei, were quantified, and the results revealed a reduction 
in the number of regenerating myofibers as well as a smaller 
mean myofiber size upon injection of miR-125b duplex on days 
5, 7, and 14 AI (Fig. 3 B). In contrast, anti–miR-125b injection 
enhanced muscle regeneration as indicated by the modest, none-
theless statistically significant, increase in regenerating myofiber 
differentiation markers, myogenin (early) and MHC (late), were 
both expressed at levels that correlated well with morphological 
differentiation upon miR-125b or anti–miR-125b expression 
(Fig. 2 G). The milder effect of anti–miR-125b on differentiation 
compared with miR-125b is consistent with its moderate impact 
on cellular miR-125b levels. Delivery of these oligonucleotides 
into C2C12 cells by transfection was assessed using the fluores-
cently labeled Dy547-cel-miR-67 (RNA duplex) and FAM-
anti-miR (single-stranded RNA), and the efficiency was 90% 
and 75%, respectively (Fig. S2 A). The degree of oligonucle-
otide up-take varied among the transfected cells for both types 
of probes (Fig. S2 A), and it is possible that maximal manipulation 
of miR-125b did not occur in all transfected cells. Nevertheless, 
the inverse relationship between miR-125b levels and degrees 
of myoblast differentiation clearly evident from our data suggests 
that miR-125b negatively regulates myogenic differentiation.
To probe a possible role of miR-125b in myoblast prolif-
eration, we examined BrdU incorporation in C2C12 cells trans-
fected with synthetic miR-125b or anti–miR-125b. As shown in 
Fig. S2 B, manipulation of miR-125b levels had no effect on 
the proliferation of myoblasts. Furthermore, introduction of 
Figure 3.  miR-125b negatively regulates skeletal muscle regeneration. Mouse TA muscles were injured with BaCl2 injection, and oligonucleotides (same 
RNA duplexes and LNA-modified oligonucleotides as in Fig. 2) were coinjected at 0.2 µg/µl as indicated. On various days AI, the TA muscles were isolated 
and either cryosectioned or extracted for RNA. As controls, saline was injected instead of BaCl2, together with the oligonucleotides, into the contralateral 
limb TA muscles. (A) Cross sections of TA muscle on day 7 AI were stained with H&E. A portion of the regenerating area is shown to provide a representa-
tive view. Bar, 50 µm. (B and C) On various days AI, regenerating myofibers (identified by their central nuclei on H&E-stained sections) were counted within 
a 614,400-µm
2 view for each sample. Cross section areas (CSA) of regenerating myofibers were quantified. At least 100 regeneration myofibers were 
measured on each muscle section. Note that the regenerating muscle area included for quantitative analysis in B and C was 10 times larger than that 
shown in A. (D) miR-125b in oligonucleotide-injected and injured muscles on various days AI was measured by qPCR. Relative miR-125b levels are shown 
with “no injury” sample set at 1 (see Fig. 1C). All results shown are mean ± SD (n = 5 mice for each data point in B and C; n = 3 mice for each data point 
in D). Paired t test was performed to compare each pair of data as indicated. *, P < 0.05; **, P < 0.01.73 miR-125b targeting IGF-II in myogenesis • Ge et al.
In conclusion, consistent with its role in myoblast differentia-
tion, miR-125b negatively impacts skeletal muscle regeneration 
in vivo. This is the first time that miR-125b is assigned a func-
tion in skeletal myogenesis.
miR-125b regulates IGF-II expression 
during myogenesis
We next asked what the molecular target or targets of miR-125b 
in myogenesis might be. miRNAs are believed to exert their 
function mostly by imperfect pairing with the 3 untranslated 
region (UTR) of target mRNAs. A seed region at the 5 end of 
the mature miRNA (starting at nt 2, up to nt 9) in the miRNA–
mRNA duplex has been found to be largely responsible for   
effective miRNA targeting (Stark et al., 2003; Krek et al., 2005; 
Lewis et al., 2005), although seedless targeting has also been 
reported (Juan et al., 2009; Lal et al., 2009; Shin et al., 2010). 
Computational  target  prediction  using  miRanda, TargetScan, 
and PicTar yielded >1,000 potential gene targets for miR-125b. 
Because miRNAs are known to induce target mRNA degrada-
tion (Baek et al., 2008; Guo et al., 2010), we looked for pre-
dicted miR-125b targets that were up-regulated at the mRNA 
level during myoblast differentiation, taking advantage of gene 
expression profiles in differentiating C2C12 cells that we had 
size on days 5, 7, and 14 AI (Fig. 3 C). The regenerating myo-
fiber number was not further increased by anti–miR-125b at any 
time during regeneration (Fig. 3 C), likely because the natural 
decline of miR-125b (Fig. 1 C) was sufficient to allow new myo-
fiber formation to reach saturation at this time point (Ge et al., 
2009). Injection of the two negative control oligonucleotides 
(siEGFP and LNA-scramble) did not have any effect on the 
normal regenerating myofiber number and size (unpublished 
data). The more modest effects of anti–miR-125b compared 
with duplex miR-125b could also be attributed to the difference 
in delivery efficiency and/or stability of the two types of oligo-
nucleotides in muscles. Indeed, after a dramatic change of miR-
125b levels in both miR-125b– and anti–miR-125b–injected 
muscles on day 1 AI, miR-125b remained elevated to a similar 
level as in noninjured muscles even on day 7 AI, whereas anti–
miR-125b injection no longer had an effect on miR-125b levels by 
day 5 AI (Fig. 3 D). We did not measure miR-125b levels beyond 
day 7 AI because it was unlikely that the injected oligonucleotides 
would remain stable in vivo for an extended time. Nevertheless, 
it is conceivable that a difference in myofiber formation could be 
observed at later time points even when the miR-125b level was 
no longer detectably changed, as an impact on the early stage of 
regeneration could change the entire time course of regeneration. 
Figure 4.  IGF-II levels are regulated by miR-125b during myoblast differentiation. (A and B) C2C12 myoblasts were transfected with 50 nM miRIDIAN 
miR-125b mimic (A) or LNA-containing anti–miR-125b (B) and, after 1 d, induced to differentiate for up to 3 d. As negative controls, miRIDIAN cel-miR-67 
and LNA-scramble were transfected side by side with miR-125b mimic and anti–miR-125b, respectively. Cells were lysed at various time points for RNA 
isolation, followed by qRT-PCR to measure IGF-II mRNA levels (left). At the same time, cell media were collected, and IGF-II protein levels were measured by 
ELISA (right). (C) On day 2 of differentiation, C2C12 myocytes were transfected with 50 nM miR-125b duplex or siEGFP (control). Total RNA was extracted 
12 h later and subjected to qPCR analysis for Igf2 mRNA (left) and miR-125b (right). (D) C2C12 myoblasts were transfected with 50 nM miR-125b duplex 
or siEGFP (control) as indicated and induced to differentiate for 3 d in the presence of 300 ng/ml recombinant IGF-II. The differentiation (diff.) and fusion 
indexes were measured. All data shown are mean ± SD from three independent experiments. Paired t test was performed to compare each pair of data in 
A, B, and D. One-sample t test was performed for data in C. *, P < 0.05; **, P < 0.01.JCB • VOLUME 192 • NUMBER 1 • 2011   74
The 3 UTR of Igf2 is targeted by miR-125b
The 3 UTR of Igf2 was predicted to contain a single miR-125b 
target site with complete complementarity in the seed region 
(Fig. 6 A), starting at nt 2670 of the 3048-bp 3 UTR. It is im-
portant to note that the major isoforms of Igf2 mRNA in C2C12 
cells, as well as in embryonic skeletal muscles, all have 3 UTR 
containing this putative miR-125b target site (Rosen et al., 
1993). To directly examine the possibility of miR-125b target-
ing Igf2 3 UTR, we constructed a reporter with the entire Igf2 3 
UTR inserted at the 3 end of the luciferase gene. We first tested 
the effect of miR-125b on this reporter in HEK293 cells, a non-
myogenic cell line which has undetectable levels of miR-125b 
(Wu et al., 2006; unpublished data). As shown in Fig. 6 B, trans-
fected miR-125b duplex drastically inhibited the reporter activ-
ity, whereas it had no effect on the control reporter without 
the 3 UTR (vector). Most importantly, when the predicted 
miR-125b seed region in the 3 UTR was mutated, the mutant 
reporter no longer responded to miR-125b (Fig. 6 B), strongly 
suggesting that the predicted site is a bona fide target of miR-125b 
and it is solely responsible for miR-125b targeting of the 
Igf2 3 UTR.
We also examined the reporters in C2C12 cells and found 
that activity of the wild-type reporter increased steadily during 
differentiation (Fig. 6 C, black bars), which is consistent with 
activation of IGF-II expression through desuppression of its 3 
UTR. The miR-125b site mutant reporter displayed a constant 
activity unchanged by the differentiation status of the cells 
(Fig. 6 C, gray bars), suggesting that miR-125b is most likely a 
major, if not the only, suppressor of the Igf2 3 UTR. Interest-
ingly, the mutant reporter activity was at the same level as the 
wild-type reporter on day 3 of differentiation, even though 
50% miR-125b remained in the cell (Fig. 1 A). This might 
suggest that the decreased miR-125b level had reached below 
the threshold for reporter inhibition. However, comparison of 
previously generated (Park and Chen, 2005). This yielded a list 
of 11 predicted genes (Table S1). Among them, Igf2 emerged as 
the most attractive candidate, as it has well-established roles in 
skeletal myogenesis (Florini et al., 1991a, 1996). It is noted that 
although the predicted miR-125b targeting sequence is identical 
in rat and mouse Igf2 genes, the human gene is different by 2 nt 
in the seed region (Fig. S3). However, the overall sequence con-
servation in the miR-125b target region between rodent and 
human Igf2 is high, and the human gene has potentially two more 
base pairings with miR-125b outside of the 6-mer seed region 
(Fig. S3). Seedless targeting of human Igf2 by miR-125b is pos-
sible, although it cannot be reliably predicted. We decided to 
focus on the mouse gene in this study as the relevant experimen-
tal systems, both in vitro and in vivo, were readily available.
To examine the possibility of miR-125b targeting IGF-II, 
we asked whether miR-125b regulated IGF-II expression. Both 
mRNA and protein levels of IGF-II increased during C2C12 
differentiation  (Fig.  4 A,  black  bars)  as  previously  reported 
(Florini et al., 1991b; Erbay et al., 2003), which correlated well 
with the drop of miR-125b levels at the same time (compare 
Fig. 4 A with Fig. 1 A). More importantly, both mRNA and pro-
tein levels of IGF-II were reduced by 60–70% on days 2 and 3 
of differentiation when a chemically modified miR-125b mimic 
(miRIDIAN) was transfected into the cells (Fig. 4 A). Native 
miR-125b duplex exerted a similar but less pronounced effect 
on IGF-II levels (unpublished data). Conversely, anti–miR-125b 
enhanced IGF-II expression at both mRNA and protein levels 
(Fig. 4 B). The degree of enhancement (1.3–2-fold) was quite 
remarkable considering that IGF-II was already up-regulated 
drastically during normal differentiation. The inhibition of 
IGF-II by miR-125b is unlikely caused by a secondary effect 
of miR-125b suppression of differentiation, as miR-125b du-
plex transfected into day 2 differentiated C2C12 myotubes po-
tently inhibited IGF-II levels only after 12 h (Fig. 4 C).
If IGF-II were a major functional target of miR-125b,   
exogenous IGF-II would be expected to override the negative   
effect of miR-125b on differentiation. Indeed, differentiation of 
C2C12 cells, as measured by differentiation and fusion indexes, 
was no longer sensitive to miR-125b duplex when the cell me-
dium was supplemented with recombinant IGF-II (Fig. 4 D). 
This suggests that IGF-II may mediate a significant portion of 
miR-125b’s negative function in myogenesis, even if Igf2 is not 
the sole target of miR-125b.
IGF-II expression increases acutely during injury-induced 
muscle regeneration, and it peaks around 5–7 d AI before de-
clining (Paoni et al., 2002; Ge et al., 2009), which inversely 
correlates with the expression pattern of miR-125b in regener-
ating  muscles  (Fig.  1  C).  Coinjection  of  miR-125b  duplex 
with the injury-inducing BaCl2 lowered Igf2 mRNA levels by 
45% on day 7 AI, and, conversely, coinjection of anti–miR-
125b increased Igf2 mRNA by 35% (Fig. 5). Injection of 
those oligonucleotides in the absence of BaCl2 did not affect 
Igf2 levels (Fig. 5, noninjured). The efficacy of delivering   
oligonucleotides into muscles might not be optimal (Fig. 3 D), 
but the observed effects are significant and fully consistent 
with miR-125b targeting IGF-II during muscle regeneration 
in vivo.
Figure 5.  IGF-II levels are regulated by miR-125b during muscle regen-
eration. Mouse TA muscles were injected with oligonucleotides alone (non-
injured) or together with BaCl2 (injured) as described in the legend for 
Fig. 3. On day 7 AI, the TA muscles were isolated for RNA extraction, 
followed by qRT-PCR assays to measure Igf2 mRNA levels. Data shown 
are mean ± SD with three mice per data point. One-sample t test was 
performed to compare each pair of data. **, P < 0.01.75 miR-125b targeting IGF-II in myogenesis • Ge et al.
Although our observations do not definitively eliminate the pos-
sibility of other miRNAs and/or target sites being involved in 
regulating Igf2 3 UTR, collectively they strongly support the 
notion that miR-125b plays a predominant role in the regulation 
of IGF-II during skeletal myogenesis.
miR-125b expression during  
myogenesis is controlled by mTOR  
in a kinase-independent manner
Previously, we had reported that mTOR regulates the expression 
of IGF-II at the transcriptional level during initiation of myo-
blast differentiation (Erbay et al., 2003). We wondered whether 
the miRNA regulation of IGF-II expression could also be con-
trolled by mTOR. To that end, we first examined the effect of 
rapamycin, a specific inhibitor of mTOR. The results of qPCR 
assays indicated that rapamycin treatment completely prevented 
the decline of mature miR-125b during differentiation in both 
C2C12 cells and primary myocytes (Fig. 7 A). The natural de-
cline of miR-125b during C2C12 differentiation and the effect 
of rapamycin to sustain miR-125b levels were also confirmed by 
Northern blotting (Fig. 7 B). To further confirm the involvement 
of mTOR in the regulation of miR-125b expression, we knocked 
down mTOR in C2C12 cells by lentivirus-delivered short hair-
pin RNA (shRNA). As shown in Fig. 7 C, knockdown of mTOR 
prevented the decline of miR-125b during differentiation; two 
shRNAs with independent target sequences yielded similar   
results, thus excluding off-target effects of RNAi. Furthermore, 
rapamycin treatment abolished the increase of Igf2 3 UTR re-
porter activity during differentiation (Fig. 7 D), as would be ex-
pected for mTOR control of miR-125b.
To gain further insight into the regulation of miR-125b 
biogenesis during myoblast differentiation, we measured the 
the absolute activities of the two reporters might not be reliable. 
The most important information derived from these data is the 
distinct trends the two reporters displayed during differentia-
tion. Furthermore, synthetic miR-125b duplex completely sup-
pressed the wild-type reporter activation during differentiation 
(Fig. 6 D). Collectively, these observations are in full agreement 
with miR-125b targeting the 3 UTR of Igf2 via a seed-containing 
site during myoblast differentiation.
It has become increasingly evident that an mRNA can 
often be targeted by multiple miRNAs in its 3 UTR. To assess 
whether the 3 UTR of Igf2 may be targeted by other miRNAs 
in addition to miR-125b, we considered all miRNAs found in 
our miRNA profiling study (Sun et al., 2010) to be down-
regulated during C2C12 differentiation (a total of 12). Other than 
miR-125b, miR-150, miR-326, and miR-805 were also predicted 
by miRanda to target Igf2 3 UTR, each at a single site (Fig. S4 A 
and not depicted). However, unlike miR-125b, which was highly 
expressed in myoblasts, the other three miRNAs were all de-
tected at very low levels in myoblasts based on our microarray 
data (unpublished data). Furthermore, whereas the miR-125b 
target site is located close to the 3 end of the 3 UTR, the pre-
dicted miR-150, miR-326, and miR-805 target sites are all lo-
cated in the middle of the 3 UTR, making them less likely to 
be true target sites (Grimson et al., 2007). Indeed, introduction 
of synthetic miR-150 duplex into HEK293 cells had no effect 
on the Igf2 3 UTR reporter (Fig. S4 B). Furthermore, when 
the putative miR-150 target site was mutated in its seed region 
(Fig. S4 A), the mutant reporter behaved identically to the wild-
type reporter during C2C12 differentiation (Fig. S4 C). These re-
sults suggest that miR-150 is unlikely to regulate Igf2, and they 
also serve as negative controls that validate the reporter assays 
(Fig. 6), identifying miR-125b as a bona fide Igf2 regulator. 
Figure 6.  miR-125b directly regulates Igf2 by targeting its 3 UTR. (A) Predicted miR-125b target site in the 3 UTR of mouse Igf2. The seed region is in 
bold, which was changed to its complementary sequence on the mutant 3 UTR reporter. Watson-Crick and wobble (G-U) base pairings are indicated by 
solid and dashed vertical lines, respectively. (B) Igf2 3 UTR reporter, its miR-125b site mutant, or vector was cotransfected with miR-125b duplex (siEGFP 
as negative control) into HEK293 cells, followed by cell lysis and luciferase assays 24 h later. (C) C2C12 myoblasts were transfected with the Igf2 3 UTR 
reporter or its miR-125b site mutant and then induced to differentiate for up to 3 d. The cells were lysed at indicated times, and luciferase assays were per-
formed. (D) C2C12 myoblasts were transfected with the Igf2 3 UTR reporter together with miR-125b duplex (siEGFP as negative control) and then induced 
to differentiate. At the times indicated, the cells were lysed and luciferase assays were performed. All data shown are mean ± SD from three independent 
experiments. Diff., differentiation; wt, wild type.JCB • VOLUME 192 • NUMBER 1 • 2011   76
RR-mTOR cells displayed miR-125b down-regulation resistant 
to rapamycin (Fig. 8 A), confirming that the effect of rapamycin 
was mediated by mTOR. Remarkably, the RR/KI-mTOR cells 
behaved  identically  to  the  RR-mTOR  cells  in  preserving 
miR-125b regulation in the presence of rapamycin (Fig. 8 B), 
indicating that the kinase activity of mTOR is not required. 
S6K1 is a major target of mTOR kinase in the regulation of cell 
growth (Fingar et al., 2002) but has been shown to be dispens-
able for mTOR regulation of IGF-II expression during myo-
genesis (Erbay et al., 2003). We found that knockdown of S6K1 
had no effect on the regulation of miR-125b during differen-
tiation (Fig. 8 C), which is consistent with kinase-independent 
mTOR regulation of miR-125b and IGF-II.
To seek in vivo validation of the aforementioned observa-
tions, we examined the effect of rapamycin on miR-125b levels 
in regenerating muscles. We found that the transient decrease of 
miR-125b during muscle regeneration in wild-type mice (days 
5 and 7 AI) was prevented by rapamycin administration (Fig. 9 A). 
This rapamycin sensitivity was absent in transgenic mice ex-
pressing  muscle-specific  RR-mTOR  (Fig.  9  B),  which  dis-
played rapamycin-resistant muscle regeneration (Ge et al., 
2009), validating the notion that rapamycin specifically targets 
levels of miR-125b primary transcripts (pri–miR-125b). Two 
genes encode miR-125b at distinct chromosomal loci: mir-125b-1 
and mir-125b-2. Although we were unable to detect pri–miR-
125b-2 by qRT-PCR, we observed a decrease of pri–miR-125b-1 
during  differentiation  that  mirrored  the  decline  of  mature 
miR-125b and was prevented by rapamycin treatment (Fig. 7 E). 
These data, together with the fact that precursor miR-125b (pre–
miR-125b) was not detectable by Northern blot analysis at any 
point of the differentiation (Fig. 7 B), imply that miR-125b bio-
genesis during myogenic differentiation is unlikely to be regu-
lated at pri–miR-125b or pre–miR-125b processing. Instead, our 
observations suggest that miR-125b is regulated at the transcrip-
tional level under the control of mTOR signaling.
Because mTOR signaling regulates IGF-II transcription 
in a noncanonical manner that is independent of mTOR kinase 
activity (Erbay et al., 2003), we decided to probe the kinase de-
pendence of mTOR regulation of miR-125b in myoblast differ-
entiation, taking advantage of C2C12 cell lines stably expressing 
rapamycin-resistant  (RR)  and  rapamycin-resistant/kinase- 
inactive (RR/KI) mTOR (Erbay et al., 2003). In contrast to pa-
rental C2C12 cells, in which rapamycin treatment prevented 
miR-125b down-regulation during differentiation (Fig. 7 A), 
Figure 7.  mTOR controls miR-125b levels during myoblast differentiation. (A) C2C12 cells and mouse primary myoblasts were induced to differentiate in 
the absence or presence of 50 nM rapamycin. Total RNA was isolated from the differentiating cells on various days as indicated (diff. day) and subjected to 
analysis by qRT-PCR to determine the relative levels of mature miR-125b. (B) RNA samples prepared from C2C12 cells as in A were subjected to Northern 
blot analysis for miR-125b and let-7a as a control. Pre–miR-125b species (71 and 77 nt) were not detected on the blot. (C) C2C12 cells were transduced 
with lentiviruses expressing two independent mTOR shRNAs and a scrambled (Scr) hairpin sequence as negative control. After puromycin selection, the 
cells were treated as in A. The inset shows Western blot results confirming mTOR knockdown. (D) C2C12 cells were transfected with the Igf2 3 UTR reporter 
and then induced to differentiate in the absence or presence of 50 nM rapamycin. The cells were lysed at the indicated times, and luciferase assays were 
performed. (E) C2C12 cells were treated as in A, and total RNA was subjected to qRT-PCR analysis for pri–miR-125b-1. All data are mean ± SD of three 
independent experiments. Paired t test was performed to compare control and rapamycin-treated samples at each time point in D. For the rest of the data, 
one-sample t test was performed to compare each data point with the control (0 h). *, P < 0.05; **, P < 0.01.77 miR-125b targeting IGF-II in myogenesis • Ge et al.
full-length Igf2 3 UTR reporter during myoblast differentiation 
(Fig. 6 C) strongly suggests that miR-125b is a major, if not the 
only, miRNA regulator of IGF-II through its 3 UTR. Further-
more, we show that the levels of miR-125b are controlled by 
mTOR signaling, shedding light on the myogenic regulation of 
miR-125b biogenesis and uncovering an additional mechanism 
by which IGF-II production is regulated by mTOR during myo-
genesis (Fig. 10).
The functions of mammalian miR-125b and its targets have 
been reported in several cellular contexts (Wu and Belasco, 2005; 
Le et al., 2009a,b), but our findings unravel for the first time a 
myogenic role for miR-125b and a new target, IGF-II. LIN-28, 
an RNA-binding protein, has been shown to regulate IGF-II 
translation during myogenesis through the recruitment of IGF-II 
mRNA  to  polysomes  (Polesskaya  et  al.,  2007).  Interestingly, 
Lin-28 is targeted by lin-4 (miR-125b homologue) in C. elegans 
(Moss et al., 1997) and by miR-125 in mouse neuronal cells (Wu 
and Belasco, 2005). Thus, it is formally possible that miR-125b 
regulation of IGF-II during myogenesis may be through targeting 
mTOR in the regenerating muscle. Strikingly, RR/KI-mTOR 
transgenic muscles, which we had previously shown to have 
normal myofiber formation but impaired fiber growth during re-
generation in the presence of rapamycin (Ge et al., 2009), also 
displayed rapamycin-resistant miR-125b down-regulation during 
regeneration (Fig. 9 C), indistinguishable from RR-mTOR mus-
cles. Therefore, we conclude that kinase-independent mTOR 
signaling is upstream of miR-125b biogenesis during skeletal 
myogenesis both in vitro and in vivo.
Discussion
Our study has identified the first miRNA regulator of IGF-II in 
skeletal myogenesis and revealed a novel function of miR-125b 
in the negative control of myoblast differentiation in vitro and 
muscle regeneration in vivo. Although it is possible that other 
miRNAs are yet to be identified to target IGF-II in myogenesis, 
our observation that mutation of the seed region of the single 
predicted miR-125b target site abolished the regulation of the 
Figure 8.  mTOR regulates miR-125b levels in myoblasts in a kinase- and S6K1-independent manner. (A and B) C2C12 cells stably expressing RR-mTOR 
(A) or RR/KI-mTOR (B) were induced to differentiate in the absence or presence of 50 nM rapamycin. Total RNA was isolated from the differentiating cells 
on various days as indicated (diff. day) and subjected to analysis by qRT-PCR to determine the relative levels of mature miR-125b. (C) C2C12 cells were 
transduced with lentiviruses expressing two independent S6K1 shRNAs and a scrambled (Scr) hairpin sequence as negative control. After puromycin selec-
tion, the cells were treated as in A and B. The inset shows Western blot results confirming S6K1 knockdown. One-sample t test was performed to compare 
each data point with the control (0 h). *, P < 0.05; **, P < 0.01. Paired t tests were also performed to compare samples within each time point, i.e., control 
with rapamycin on each day in A and B and S6K1 shRNA with scramble in C. No significant difference was found.
Figure 9.  mTOR regulates miR-125b levels in regenerating muscles in a kinase-independent manner. (A) TA muscles of wild-type (WT) mice were injected 
with BaCl2, and the contralateral muscles were injected with saline as controls (no injury), followed by systemic administration of rapamycin daily from   
day 1 AI. On various days AI, total RNA was isolated from the TA muscles and subjected to analysis by qRT-PCR to determine the relative levels of mature 
miR-125b. (B and C) Transgenic mice expressing RR-mTOR (B) or RR/KI-mTOR (C) in skeletal muscle were treated as described in A. All data shown are 
mean ± SD (n = 4 mice for each condition). One-sample t test was performed to compare each data point with the control (no injury). *, P < 0.05.JCB • VOLUME 192 • NUMBER 1 • 2011   78
reduction below the threshold level at the initiation of differ-
entiation allows full-blown IGF-II production activated at the 
transcriptional and translational levels.
Almost all of the myogenic miRNAs reported thus far are 
up-regulated during differentiation, with the exception of miR-
221/222, which have been reported to be down-regulated and 
negatively regulate myogenesis in quail through the previously 
known target p27 (Cardinali et al., 2009). Compared with   
miRNAs that are often drastically up-regulated during myogenesis, 
miR-125b is down-regulated to less dramatic degrees during 
both myoblast differentiation and muscle regeneration (Fig. 1), 
similar to the degree of changes of miR-221/222 upon C2C12 
myoblast differentiation (Cardinali et al., 2009). This is consis-
tent with the fact that miRNAs are generally very stable (Lee   
et al., 2003; Lund et al., 2004). Nevertheless, the partial reduc-
tion of miR-125b is apparently sufficient and necessary to allow 
IGF-II expression and myogenic differentiation.
Our results also raise the distinct possibility of myogenic 
regulation of miR-125b biogenesis at the transcriptional level 
rather than the maturation steps, under the control of mTOR sig-
naling. Further dissection of mechanisms underlying miR-125b 
biogenesis will require identification of the regulatory elements 
for the two miR-125b genes. Most recently, we have discovered 
a myogenic pathway in which mTOR regulates miR-1 biogene-
sis through MyoD (Sun et al., 2010). However, mTOR regula-
tion of miR-125b would likely be through a different mechanism 
because it results in the decrease of miR-125b during myogene-
sis, in contrast to the increase of miR-1. Until such a mechanism 
is delineated, we do not know how remotely or proximately 
mTOR lies from miR-125b in its biogenic pathway. In any event, 
mTOR clearly regulates the biogenesis of these two miRNAs 
through distinct pathways, one dependent (miR-1; Sun et al., 
2010) and one independent (miR-125b) of its kinase activity. 
It is interesting that this kinase-independent function of mTOR 
controls myogenic IGF-II production at two levels: transcrip-
tional regulation through a muscle-specific enhancer (Erbay et al., 
2003) and posttranscriptional regulation through miR-125b. This 
dual control underlines the importance of the mTOR–IGF-II 
axis in the regulation of skeletal myogenesis. Whether a single 
noncanonical mTOR pathway controls both processes or there 
are two distinct kinase-independent mTOR mechanisms will 
be a fascinating topic for future investigation.
Materials and methods
Antibodies and other reagents
Anti-MHC (MF20) and antimyogenin (F5D) were obtained from the Devel-
opmental Studies Hybridoma Bank developed under the auspices of the 
Eunice Kennedy Shriver National Institute of Child Health and Human De-
velopment, National Institutes of Health and maintained by The University 
of Iowa Department of Biological Sciences. Antitubulin was purchased 
from Abcam. Anti-BrdU was purchased from Sigma-Aldrich. All secondary 
antibodies were obtained from Jackson ImmunoResearch Laboratories, Inc. 
Rapamycin was obtained from LC Laboratories. All other reagents were 
purchased from Sigma-Aldrich.
Cell culture and transfection
C2C12 myoblasts were maintained in DME containing 1 g/l glucose with 
10% fetal bovine serum at 37°C with 7.5% CO2. Primary myoblasts were 
maintained in F-10 medium supplied with 25 ng/ml bFGF and 20% fetal 
Lin-28 (Fig. 10). Although our results do not rule out this possi-
bility, they provide convincing evidence to support a direct miR-
125b–IGF-II relationship: (a) miR-125b inhibits Igf2 3 UTR 
reporter activity through a seed-containing target site in HEK293 
cells (Fig. 6 B), where Lin-28 is not expressed (Moss and Tang, 
2003); (b) the mRNA levels of IGF-II are regulated by miR-125b 
in myocytes and muscles (Fig. 4, A–C; and Fig. 5), which cannot 
be explained by LIN-28 as a mediator because LIN-28 regulates 
the translation of IGF-II (Polesskaya et al., 2007).
Coordinate  targeting  of  multiple  genes  in  a  functional 
pathway or protein complex has emerged as a common theme 
for many miRNAs (Tsang et al., 2010). For example, miR-24 
coordinately targets a network of cell cycle regulators to facili-
tate cell cycle exit upon cellular differentiation (Lal et al., 2009); 
let-7 acts as a tumor suppressor by targeting multiple genes in-
volved in cell proliferation (Johnson et al., 2007). However, in 
the case of miR-125b regulating myogenesis, the complete res-
cue of myoblast differentiation by recombinant IGF-II from the 
inhibitory effect of miR-125b overexpression (Fig. 4 D) is con-
sistent with IGF-II being a major, if not the only, target of miR-
125b. Although we cannot rule out the possibility of miR-125b 
targeting additional myogenic genes, our current observations 
collectively suggest that the miR-125b–IGF-II relationship is 
functionally dominant in the regulation of myogenesis.
As a critical inducer of skeletal myogenesis both in vitro 
and in vivo, it is not surprising that the myogenic production of 
IGF-II is tightly controlled by multiple mechanisms. The tran-
scription  of  IGF-II  is  regulated  through  a  muscle-specific 
enhancer by mTOR signaling (Erbay et al., 2003), and the trans-
lation of IGF-II during skeletal myogenesis is regulated by Lin-28 
(Polesskaya et al., 2007). Our current study adds a new layer 
of  mechanism, through an miRNA, that modulates both the 
mRNA and protein levels of IGF-II. It is generally believed that 
miRNAs play fine-tuning roles in the control of gene expres-
sion; miR-125b targeting of IGF-II in coordination with tran-
scriptional and translational controls is a perfect example of that 
principle. The strong but incomplete effects of overexpressing 
or antagonizing miR-125b on IGF-II expression, myogenic dif-
ferentiation, and muscle regeneration (Figs. 2–4) are certainly 
in line with the modulating nature of miR-125b. It is reasonable 
to speculate that miR-125b serves as a gatekeeper to suppress 
IGF-II expression before cells commit to differentiation, and its 
Figure 10.  A model for the regulatory network involving IGF-II in myo-
genesis. Kinase-independent mTOR signaling regulates IGF-II production 
at a transcriptional level as well as a posttranscriptional level through 
miR-125b. miR-125b control of IGF-II expression may also be mediated 
by Lin-28 at a translational level.79 miR-125b targeting IGF-II in myogenesis • Ge et al.
BrdU labeling
Subconfluent C2C12 myoblasts were incubated in BrdU (final concentra-
tion 10 µM) under growth condition for 2 h and then fixed with 3.7% form-
aldehyde.  After  treatment  by  4N  HCl,  immunostaining  with  anti-BrdU 
antibody and FITC-labeled anti–mouse IgG was carried out, and fluores-
cence microscopy was performed as described in Immunofluorescence 
microscopy and quantitative analysis of myocytes.
Western blotting
Cells were lysed in a buffer containing 50 mM Tris-HCl, pH 7.2, 150 mM 
NaCl, 1% NP-40, and 1% protease inhibitor cocktail (Sigma-Aldrich). The 
lysates were cleared by microcentrifugation at 14,000 rpm and then mixed 
with SDS sample buffer. Proteins were resolved on SDS-PAGE and trans-
ferred onto polyvinylidene fluoride membrane (Millipore) and incubated 
with various antibodies according to the manufacturer’s recommendations. 
Detection  of  horseradish  peroxidase–conjugated  secondary  antibodies 
was performed with Western Lightning Chemiluminescence Reagent Plus 
(PerkinElmer), and images were developed on x-ray films. Quantification of 
Western blot band intensities was performed by densitometry of x-ray 
images using the software ImageJ (National Institutes of Health).
Immunofluorescence microscopy and quantitative analysis of myocytes
C2C12 cells differentiated in 12-well plates were fixed and stained for MHC 
and DAPI as previously described (Park and Chen, 2005). The stained cells 
were examined with a DMI 4000B microscope with a 10× dry objective 
(Fluotar, numerical aperture 0.4), and the fluorescent images were captured at 
8 bit at room temperature using a RETIGA EXi camera equipped with Qcap-
ture Pro51 software. The images were then pseudocolored in Photoshop CS2, 
where brightness and contrast were adjusted. The differentiation and fusion in-
dexes were calculated as the percentage of nuclei in MHC-positive myocytes 
and myotubes with at least two nuclei, respectively. Each data point was gen-
erated from at least 200 randomly chosen MHC-positive cells or myotubes.
Real-time qPCR
Mouse TA muscles were isolated, ground into powder in liquid nitrogen, 
and lysed in TRIZOL (Invitrogen). C2C12 cells or mouse primary myoblasts 
were lysed directly in TRIZOL. RNA was isolated according to the manufac-
turer’s protocol. qRT-PCR for Igf2 mRNA was performed as previously de-
scribed (Yoon and Chen, 2008). miR-125b levels were quantified using a 
qPCR-based TaqMan assay kit (Applied Biosystems) specifically designed 
for miR-125b (not miR-125a). SnoRNA-202, a commonly used mouse inter-
nal reference, was used as the internal control for normalization. We con-
firmed that Ct values of snoRNA-202 did not change from sample to sample 
in any systematic manner under all conditions.
Lentivirus-mediated RNAi
shRNAs in the pLKO.1-puro vector for knocking down mTOR and S6K1 
were purchased from Sigma-Aldrich (MISSION TRC). Lentivirus packaging 
and testing were performed as previously described (Yoon and Chen, 2008). 
The Sigma-Aldrich clone IDs for the shRNA constructs used in this study are 
mTOR #1, NM_020009.1-7569s1c1; mTOR #2, NM_020009.1-5493s1c1; 
S6K1 #1, NM_028259.1-264s1c1; and S6K1 #2, NM_028259.1-616s1c1.   
C2C12 cells were transduced with lentiviruses in growth medium contain-
ing 8 µg/ml polybrene and selected in 3 µg/ml puromycin for 1 d, followed 
by plating into 12-well plates for differentiation.
Luciferase assays
C2C12 or HEK293 cells transfected with wild-type or mutant Ig2 3 UTR 
reporter were lysed in passive lysis buffer (Promega), and luciferase assays 
were performed using the Luciferase Assay Systems kit (Promega) accord-
ing to the manufacturer’s protocol.
Measurement of secreted IGF-II
Media were collected from differentiating C2C12 cultures and subjected to 
measurement of secreted IGF-II using the DuoSet ELISA Development System 
for mouse IGF-II (R&D Systems) according to the manufacturer’s protocol.
Statistical analysis
All data are presented as mean ± SD. Whenever necessary, statistical sig-
nificance of the data was analyzed by performing one-sample t tests or 
paired t tests. The specific types of tests and the p-values, when applicable, 
are indicated in the figure legends.
Online supplemental material
Fig. S1 shows miR-1 and miR-206 levels in regenerating skeletal muscles. 
Fig. S2 shows that miR-125b does not affect proliferation of C2C12 cells. 
bovine serum at 37°C with 7.5% CO2. To induce differentiation, cells were 
plated on tissue culture plates coated with 0.2% gelatin and grown to 
100% confluence for C2C12 and 60–70% confluence for primary myo-
blasts, changed into differentiation medium (DME containing 2% horse 
serum), and replenished with fresh medium daily for 3 (C2C12) or 2 d 
(primary myocytes). C2C12 myoblasts and myocytes were transfected 
using Lipofectamine 2000 (Invitrogen) for RNA duplexes. Introduction of 
LNAs and luciferase reporters into C2C12 cells was performed using 
Nucleofector (solution V, program B-032; Lonza) according to the manu-
facturer’s recommendations. HEK293 cells were maintained in DME con-
taining 4.5 g/l glucose with 10% fetal bovine serum at 37°C with 5% CO2 
and transfected using Polyfect (QIAGEN).
Mouse primary myoblast isolation
All animal experiments in this study followed protocols approved by the 
Animal Care and Use Committee at the University of Illinois at Urbana-
Champaign. 5–7-d-old neonates were euthanized by cervical dislocation 
and rinsed in 70% ethanol and penicillin/streptomycin/Fungizone anti-
biotic solution. Hind leg muscles were isolated and minced in HBSS and di-
gested in 2.4 U/ml dispase II (Roche) and 1.5 U/ml collagenase D (Roche) 
solution containing 2.5 mM CaCl2 at 37°C for 2 h. Upon sequential filter-
ing through 70- and 40-µm cell strainers (BD), the cells were collected by 
centrifugation at 350 g and resuspended in F-10 culture medium. Serial 
plating was performed to enrich myoblasts and eliminate fibroblasts.
Mouse muscle injury and regeneration
10-wk-old male FVB mice were used in all the regeneration experiments. 
Muscle injury was induced by injection of BaCl2 (50 µl of 1.2% wt/vol in 
saline) into TA muscles as previously described (Ge et al., 2009). On vari-
ous days AI, the mice were euthanized, and the TA muscles were collected, 
followed by cryosection and staining as described in the next section.
Muscle tissue cryosection and analysis
TA muscles were isolated by dissection, frozen in liquid nitrogen–cooled   
2-methylbutane, and embedded in TBS tissue freezing medium (Thermo 
Fisher Scientific). Sections of 10-µm thickness were made with a cryostat 
(Microm HM550; Thermo Fisher Scientific) at 20°C, placed on uncoated 
slides, and stained with hematoxylin and eosin (H&E). The stained slides 
were examined with a microscope (DMI 4000B; Leica) with a 10× dry ob-
jective (Fluotar, numerical aperture 0.4; Leica), and the brightfield images 
were captured at 24 bit at room temperature using a camera (RETIGA EXi; 
QImaging) equipped with Qcapture Pro51 software (QImaging). The   
images were then processed in Photoshop CS2 (Adobe), where brightness 
and contrast were adjusted. An area of 614,400 µm
2 at the center of de-
generated region of each TA muscle was selected for scoring centrally nu-
cleated regenerating myofiber numbers and their cross section area.
Plasmids and oligonucleotides
The Igf2 3 UTR reporter was generated by inserting the entire 3 UTR of 
mouse  Igf2  gene  into  the  pMIR-REPORTER  vector  (Applied  Biosystems) 
downstream of the luciferase gene through MluI and PmeI sites. The mutant 
Igf2 3 UTR reporters were created by mutating the seed region of the pre-
dicted miR-125b site (UCAGGG to AGUCCC) or miR-150 site (GUUG-
GGAG to CAACCCUC) by nested PCR. RNA duplexes for miRNAs and 
siEGFP (siRNA against EGFP) and LNA-containing oligonucleotides were 
custom synthesized by Integrated DNA Technology. The sequences of the 
LNA oligonucleotides are as follows, with LNA-modified nucleotides indi-
cated by capital letters: anti–miR-125b, 5-tcacaagTTAGGGTCtcaggga-3 
(distinguishable from miR-125a by two LNA-modified nucleotides); and 
scramble, 5-catgtcaTGTGTCACatctctt-3. miRIDIAN miR-125b mimic and 
a negative control (cel-miR-67; which has minimal sequence identity with 
miRNAs in human, mouse, and rat) were purchased from Thermo Fisher 
Scientific. Dy547-cel-miR-67 and FAM-anti-miR negative control were ob-
tained from Thermo Fisher Scientific and Applied Biosystems, respectively.
Northern blotting
Antisense DNA oligonucleotides for miR-125b and let-7a were end labeled 
with -[
32P]ATP. The RNA Decade Maker (Applied Biosystems) was simi-
larly radiolabeled as size markers. RNA (20 µg per sample) was separated 
on 12% denaturing polyacrylamide gels, transferred to nylon membranes 
(GE Healthcare), and UV cross-linked. Prehybridization and hybridization 
with probe were performed in ULTRAhyb hybridization buffer (Applied Bio-
systems) at 42°C for 2 h and overnight, respectively. The membranes were 
then washed with 2× SSC and 0.1% SDS at 42°C, followed by exposure 
to x-ray films.JCB • VOLUME 192 • NUMBER 1 • 2011   80
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